Encapsulation of bioactive compounds in the liposome system provides several advantages, such as enhancing the stability and lowering the toxicity of active compounds. Coffee berry extract (CBE) has previously been established to have in vitro anti-aging properties and to retard the aging of human skin. The purposes of this study were to encapsulate CBE in nanoliposomes and to assess its stability and in vitro anti-aging potential in human dermal fibroblasts (HDF), as well as in healthy human skin. In the HDF model, anti-aging potential was determined by nitric oxide (NO) and collagenase inhibition assays and a superoxide dismutase (SOD) activity assay, whereas in healthy human skin (in vivo), the skin elasticity and brightness were examined. First, liposomal CBE (L-CBE) was created with a particle size of 117.33 ± 2.91 nm, a polydispersity index (PDI) of 0.36 ± 0.03, and a zeta potential of −56.13 ± 1.87 mV. The percentages of encapsulation efficacy (%EE) and loading efficacy (%LE) were 71.26 ± 3.12% and 2.18 ± 0.18%, respectively. After undergoing a 12-week stability test, the L-CBE retained more phenolic content than the free CBE when stored at 4 °C, room temperature, and 45 °C. Compared to free CBE, the L-CBE demonstrated a more consistent, elevated, and prolonged release of phenolics from the lipid system. In human dermal fibroblasts, L-CBE showed lower toxicity, and at its maximum nontoxic concentration (10 mg/mL), it exhibited slightly higher anti-aging effects than CBE, including NO inhibition, enhanced SOD activity, and anti-collagenase activities. In clinical trials (30 volunteer subjects), none of the participants’ skin was irritated when the L-CBE, the CBE, or base creams were applied. After 2 weeks of application, the L-CBE and CBE creams both demonstrated an improvement in skin elasticity and a reduction in melanin levels, and after 4 weeks, L-CBE cream showed a significantly greater improvement in skin elasticity and lightening. The results demonstrate that the encapsulation of the CBE in liposomal systems could increase its stability and skin penetration, reduce its toxicity, and maintain its anti-aging effect, which is powerful enough to be exploited in anti-aging and whitening agents for application in cosmetics and cosmeceuticals.

The Eleutherine bulbosa bulb has been reported as a potent antioxidant in food. This work aims to extract the E. bulbosa bulb for use as an antioxidative agent in cosmetics. Water, 95% ethanol (EtOH), and propylene glycol (PG), which are normally used in cosmetic formulation, were employed as green and sustainable extraction solvents. EtOH and PG displayed better candidacy to extract active components from E. bulbosa bulbs than using water, and the mixture of EtOH and PG (EtOH/PG) resulted in the extract with higher bioactive compounds and biological activities compared with using EtOH or PG. The total phenolic content of the EtOH/PG extract was 87.60 ± 2.00 mgGAE/mL which was about an 18–23% increase from when using single EtOH or PG (70.91 ± 2.30, 74.05 ± 0.67 mgGAE/mL). UHPLC-ESI-QTOF-MS/MS analysis showed that the E. bulbosa bulb extracted in EtOH/PG was composed of naphthalenes, naphthoquinones, anthraquinones, myricetin, quercetin, epicatechin, catechin, epigallocatechin, and their derivatives. The ethanolic crude extract exhibited anti-elastase and anti-collagenase activity with the IC₅₀ of 7.76 ± 0.35 and 0.53 ± 0.23 mg/mL, respectively, and was non-cytotoxic to human dermal fibroblast cells at 0.0001–1 mg/mL. The emulsion cream containing 2%(w/w) E. bulbosa bulb concentrated extract was found cosmetically stable after a one-month stability test under 4 °C, ambient temperature (30–35 °C), 45 °C, fluorescent light, and daylight. However, exposure to sunlight during daytime caused changes in the emulsion’s color with ΔE* of 3.85 ± 0.08, and at 45 °C caused the 12% decrease in DPPH activity of emulsion. The finding of this work heightens the antioxidative and safety potentials of the E. bulbosa bulb in cosmetic preparations.

In this study, zinc oxide nanoparticles (ZnO NPs) were synthesized via a green chemistry approach using aqueous extract of Camellia sinensis var. assamica (Assam green tea) as a bioreductant and stabilizing agent. Phytochemical analysis of the extract revealed high levels of phenolics (338.57 ± 3.90 mg GAE/mL) and flavonoids (123.92 ± 1.34 µg QE/mL), along with strong antioxidant and reducing activity, supporting its efficacy in nanoparticle formation. ZnO NPs were synthesized at various extract concentrations, with 25% yielding optimal characteristics based on UV–Vis spectrophotometry (λ_Max ≈ 390–410 nm). Structural characterization using XRD confirmed the hexagonal wurtzite phase, and SAXS indicated particle sizes of 58–60 nm. FE-SEM analysis showed semi-spherical agglomerated particles ranging from 74 to 76 nm, while EDX verified the elemental purity of Zn and O. FT-IR spectroscopy confirmed the presence of Zn–O stretching and phytochemical residues on the nanoparticle surface. Stability studies over four weeks revealed red shifts in absorbance and reduced peak intensity at ambient and elevated temperatures, suggesting nanoparticle agglomeration. Antimicrobial assays demonstrated strong antifungal activity of the ZnO NP solution against Candida albicans and, upon concentration, significant antibacterial activity against Streptococcus mutans. The synthesized ZnO NPs exhibit promising potential as eco-friendly antimicrobial agents, particularly for applications in oral healthcare.